Nimodipine
(Synonyms: 尼莫地平; BAY-e 9736) 目录号 : GC16587
Nimodipine是一种1,4-二氢吡啶类L型钙离子通道拮抗剂,主要用于治疗动脉瘤性蛛网膜下腔出血(aSAH),预防脑血管痉挛。
Cas No.:66085-59-4
Sample solution is provided at 25 µL, 10mM.
Nimodipine is a 1,4-dihydropyridine L-type calcium channel antagonist, mainly used to treat aneurysmal subarachnoid hemorrhage (aSAH) and prevent cerebral vasospasm[1]. Nimodipine can block voltage-dependent calcium channels, reduce calcium influx, protect neurons, and reduce oxidative stress and cell apoptosis[2, 3].
In vitro, pretreatment of PC12 cells with Nimodipine (20μM) for 48h significantly reduced the cytotoxic effects of EtOH and osmotic stress on cells, but had no effect on hypoxia-induced cytotoxicity[4]. Pretreatment of Schwann cells, neurons and astrocytes with Nimodipine (1, 10, 20μM) for 24h reduced the cytotoxic effects of EtOH, osmotic pressure and heat stress on cells in a dose-dependent manner[5].
In vivo, Nimodipine (5, 10, 15mg/kg) was intraperitoneally injected into rats with experimental myocardial infarction for 7 days, which improved the hemodynamic parameters of rats, reversed the histopathological and ultrastructural changes, increased endogenous antioxidants, maintained the serum levels of myocardial biomarkers CK-MB, LDH, SGOT, Trop-T and cGMP, and showed a more powerful cardioprotective effect when combined with vinpocetine[6].
References:
[1] Wiputri O I, Hidayati H B. The Role of Nimodipine as a Neurorestorative Drug in Preventing Cerebral Vasospasm Related to Subarachnoid Aneurysmal Hemorrhage[J]. Int J Pharma Res Health Sci, 2019, 7(6): 3079-83.
[2] Singh A, Verma P, Balaji G, et al. Nimodipine, an L-type calcium channel blocker attenuates mitochondrial dysfunctions to protect against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced Parkinsonism in mice[J]. Neurochemistry international, 2016, 99: 221-232.
[3] Kusakabe M, Hasegawa Y. Nimodipine promotes neurite outgrowth and protects against neurotoxicity in PC12 cells[J]. Iranian journal of basic medical sciences, 2021, 24(1): 51.
[4] Bork K, Wurm F, Haller H, et al. Neuroprotective and neuroregenerative effects of nimodipine in a model system of neuronal differentiation and neurite outgrowth[J]. Molecules, 2015, 20(1): 1003-1013.
[5] Leisz S, Simmermacher S, Prell J, et al. Nimodipine-dependent protection of schwann cells, astrocytes and neuronal cells from osmotic, oxidative and heat stress is associated with the activation of AKT and CREB[J]. International Journal of Molecular Sciences, 2019, 20(18): 4578.
[6] Ansari M A, Iqubal A, Ekbbal R, et al. Effects of nimodipine, vinpocetine and their combination on isoproterenol-induced myocardial infarction in rats[J]. Biomedicine & Pharmacotherapy, 2019, 109: 1372-1380.
Nimodipine是一种1,4-二氢吡啶类L型钙离子通道拮抗剂,主要用于治疗动脉瘤性蛛网膜下腔出血(aSAH),预防脑血管痉挛[1]。Nimodipine能够阻断电压依赖性钙通道,减少钙离子内流,对神经元具有保护作用,还能够减轻氧化应激和细胞凋亡[2, 3]。
在体外,Nimodipine(20μM)预处理PC12细胞48h,显著降低了EtOH和渗透压应激条件对细胞的细胞毒性作用,而对缺氧诱导的细胞毒性无影响[4]。Nimodipine(1, 10, 20μM)预处理Schwann细胞、神经元细胞和星形胶质细胞24h,以剂量依赖性方式降低了EtOH、渗透压和热应激条件对细胞的细胞毒性作用[5]。
在体内,Nimodipine(5, 10, 15mg/kg)通过腹腔注射治疗实验性心肌梗死大鼠7天,改善了大鼠血液动力学参数,逆转了组织病理学和超微结构的变化,增加了内源性抗氧化剂,维持了心肌生物标志物CK-MB、LDH、SGOT、Trop-T和cGMP的血清水平,且与Vinpocetine联合用药表现出了更强大的心脏保护作用[6]。
Cell experiment [1]: | |
Cell lines | PC12 cells |
Preparation Method | Cells were seed on Collagen IV coated plates and allowed to attach for 24h. Afterwards cells were pretreated with 20μM Nimodipine or DMSO for 48h. Alcohol stress: Medium was changed and cells were treated with 200mM EtOH and 20µM Nimodipine or DMSO and incubated for 48h. Osmotic stress: Medium was changed and cells were treated with additional NaCl to increase the osmotic concentration from 290 to 450mosmol/L and 20µM Nimodipine or DMSO and incubated for 48h. |
Reaction Conditions | 20μM; 48h |
Applications | Cytotoxicity of 200mM EtOH and osmotic stress (450mosmol/L) was significantly reduced with Nimodipine pretreatment, while Nimodipine has no influence on the hypoxia-induced cytotoxicity in PC12 cells. |
Animal experiment [2]: | |
Animal models | Wistar albino rats |
Preparation Method | Rats were randomly divided into Group I-Vehicle Control Group; Group II-Toxic control (ISO 85mg/kg, i.p.); Group III, IV and V-Nimodipine (5, 10 and 15mg/kg, i.p. respectively) with ISO; Group VI-Nimodipine (15mg/kg) alone; Group VII–Nimodipine+Vinpocetine (10mg/kg+10mg/kg) with ISO; Group VIII-Nimodipine+Vinpocetine (10mg/kg+10mg/kg) alone; Group IX-Diltiazem (25mg/kg, p.o) with ISO; Group X-Diltiazem (25mg/kg) alone and Group XI-Vinpocetine (10mg/kg, p.o.) with ISO for 7 days. After 24h of the last dose, haemodynamics were assessed then animals were sacrificed and biochemical, histopathological and ultrastructural changes were measured. |
Dosage form | 5, 10, 15mg/kg; 7 days; i.p. |
Applications | Combination of Nimodipine with Vinpocetine exhibit strong cardioprotective effect. This combination improved haemodynamic parameters, reversed changes at the histopathological and ultrastructural level, increased endogenous antioxidants and maintained the serum levels of cardiac biomarkers CK-MB, LDH, SGOT, Trop-T and cGMP. |
References: |
Cas No. | 66085-59-4 | SDF | |
别名 | 尼莫地平; BAY-e 9736 | ||
化学名 | 3-O-(2-methoxyethyl) 5-O-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate | ||
Canonical SMILES | CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCOC | ||
分子式 | C21H26N2O7 | 分子量 | 418.45 |
溶解度 | ≥ 108mg/mL in DMSO, ≥ 41.8mg/mL in EtOH | 储存条件 | Store at -20°C,protect from light |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 2.3898 mL | 11.9489 mL | 23.8977 mL |
5 mM | 0.478 mL | 2.3898 mL | 4.7795 mL |
10 mM | 0.239 mL | 1.1949 mL | 2.3898 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet